BioPharmSignal logoBioPharmSignal

Biotech News

Enlivex Announces $400,000,000 Private Placement

Enlivex Therapeutics (ENLV)Enlivex TherapeuticsFinancing

Nes-Ziona, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or "the Company"), a quality longevity company powered by a prediction markets treasury, today announced that it has entered into a securities purchase agreement with a single institutional investor with respect to the private placement of $400,000,000 of...

Related news

CUECue Biopharma Inc2026-07-10 01:40 EST

Cue Biopharma Announces $50.0 Million Private Placement

ENLVEnlivex Therapeutics2026-07-30 13:00 EST

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

MDNAMedicenna Therapeutics Corp.2026-05-19 11:00 EST

Medicenna Announces the Finalization of the Terms of its Public Offering of Securities

MDNAMedicenna Therapeutics Corp.2026-05-13 20:01 EST

Medicenna Announces the Launch of a Marketed Public Offering of Securities

BCTXBriaCell2026-06-02 20:05 EST

BriaCell Therapeutics Announces Closing of Offering

ELTXElicio Therapeutics, Inc.2026-07-06 20:05 EST

Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering

ELTXElicio Therapeutics, Inc.2026-07-02 04:25 EST

Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering

BCTXBriaCell2026-05-31 23:59 EST

BriaCell Therapeutics Announces Pricing of Offering

IMNNImunon2026-06-04 12:00 EST

IMUNON Announces Up to $10 Million Cash Financing

View all latest news

Enlivex Therapeutics

Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.

Recent company news

ENLVEnlivex Therapeutics2026-07-30 13:00 EST

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

Stock data

Close
1.98 USD
Market cap
204.87M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States